Paul-Albert Legrand and Mathilde Celestin advised FineHeart in connection with the second closing of its Series C financing. This new tranche, amounting to €35 million, brings together new investors, including Groupe Pasteur Mutualité and Groupe Etchart, alongside existing investors, notably the European Innovation Council (EIC) Fund, FH Founders, Lurra Capital, IRDI Capital Investissement, Nouvelle Aquitaine Co-Investissement (NACO) and Groupe Doliam.

FineHeart is a French clinical-stage medtech company specializing in the development of innovative implantable medical devices for the treatment of severe heart failure.